Explore

Trendline Trendline
Merck Adjusts Acquisition Offer for Terns Pharmaceuticals After Leukemia Data Update

Merck Adjusts Acquisition Offer for Terns Pharmaceuticals After Leukemia Data Update

Merck Adjusts Acquisition Offer for Terns Pharmaceuticals After Leukemia Data Update
Trendline Trendline
Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment

Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment

Phanes Therapeutics Expands Clinical Study of Spevatamig for Biliary Tract Cancer Treatment
Trendline Trendline
Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma

Allucent Expands Leadership to Enhance Drug Development for Biopharma
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges
Trendline Trendline
Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds
Trendline Trendline
Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges
Trendline Trendline
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors